Skip to main
EPRX

EPRX Stock Forecast & Price Target

EPRX Analyst Ratings

Based on 4 analyst ratings
Buy
Strong Buy 50%
Buy 50%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Eupraxia Pharmaceuticals is well-positioned to capture a significant market share in the treatment of osteoarthritis and eosinophilic esophagitis symptoms with its drug EP-104. The company's proprietary Diffusphere technology sets it apart from competitors, providing a highly effective and durable treatment option, with a favorable safety profile. The recent appointment of Dr. Jeymi Tambiah, with a strong background in osteoarthritis research, further strengthens the company's potential in this area. With a clear clinical gap and potential for expansion into additional indications, Eupraxia Pharmaceuticals has a strong case for success and a promising future ahead.

Bears say

Eupraxia Pharmaceuticals is facing significant challenges with its clinical development and future commercial viability, as EP-104GI, its main product, targets niche conditions with high competition and potentially limited market demand. Additionally, the company's financials show a heavy reliance on financing and a high weighted average cost of capital, adding to the risk profile and potential for future funding difficulties. With these factors in mind, analysts have a negative outlook on the stock and believe there are significant risks to achieving the projected value and success of EP-104GI.

EPRX has been analyzed by 4 analysts, with a consensus rating of Buy. 50% of analysts recommend a Strong Buy, 50% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Eupraxia Pharmaceuticals Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Eupraxia Pharmaceuticals Inc (EPRX) Forecast

Analysts have given EPRX a Buy based on their latest research and market trends.

According to 4 analysts, EPRX has a Buy consensus rating as of Sep 13, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $18, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $18, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Eupraxia Pharmaceuticals Inc (EPRX)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.